

## HR 7008

### Pre-approval Information Exchange Act of 2022

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Mar 9, 2022

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Mar 10, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/7008>

### Sponsor

**Name:** Rep. Guthrie, Brett [R-KY-2]

**Party:** Republican • **State:** KY • **Chamber:** House

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Griffith, H. Morgan [R-VA-9]	R · VA		Mar 30, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 10, 2022

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

*No related bills are listed.*

### Summary (as of Mar 9, 2022)

#### Pre-approval Information Exchange Act of 2022

This bill specifies that economic, scientific, or other product support information that is exchanged between drug manufacturers and health care entities (e.g., pharmacy benefit managers) about drug products before regulatory approval is not considered to be misbranding or prohibited premarket promotion if it relates to the product's investigational use and meets other specified criteria. The Government Accountability Office must study the use and effects of such information.

### Actions Timeline

- **Mar 10, 2022:** Referred to the Subcommittee on Health.
- **Mar 9, 2022:** Introduced in House
- **Mar 9, 2022:** Referred to the House Committee on Energy and Commerce